ArticleCurrent pathobiology reports2017
MicroRNAs in Cancer: challenges and opportunities in early detection, disease monitoring, and therapeutic agents.
Article in Current pathobiology reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Can MicroRNAs serve as reliable biomarkers and novel therapeutic targets in age-related macular degeneration? A systematic review and meta-analysis.Journal of translational medicine · 2026Pooled it
- Utility of Urinary miRNA Biomarkers for Canine Urothelial Carcinoma Diagnostics.Veterinary sciences · 2025Article
- MicroRNA 211-5p inhibits cancer cell proliferation and migration in pancreatic cancer by targeting BMP2.Aging · 2023Article
- MicroRNA as a Diagnostic Tool, Therapeutic Target and Potential Biomarker in Cutaneous Malignant Melanoma Detection-Narrative Review.International journal of molecular sciences · 2023Review
- miRNA Profiles of Canine Intestinal Carcinomas, Lymphomas and Enteritis Analysed by Digital Droplet PCR from FFPE Material.Veterinary sciences · 2023Article
- Mesenchymal stem cell-derived extracellular vesicles for cell-free therapy of ocular diseases.Extracellular vesicles and circulating nucleic acids · 2022Review
- Potentiality of Exosomal Proteins as Novel Cancer Biomarkers for Liquid Biopsy.Frontiers in immunology · 2022Review
- Cervical cancer development, chemoresistance, and therapy: a snapshot of involvement of microRNA.Molecular and cellular biochemistry · 2021Review
- Optimization of Tumor Disease Monitoring in Medical Big Data Environment Based on High-Order Simulated Annealing Neural Network Algorithm.Computational intelligence and neuroscience · 2021Article
- Bortezomib Sustains T Cell Function by Inducing miR-155-Mediated Downregulation of SOCS1 and SHIP1.Frontiers in immunology · 2021Article
- MicroRNA Expression Profiling on Paired Primary and Lymph Node Metastatic Breast Cancer Revealed Distinct microRNA Profile Associated With LNM.Frontiers in oncology · 2020Article
- Upregulated hsa_circ_0004458 Contributes to Progression of Papillary Thyroid Carcinoma by Inhibition of miR-885-5p and Activation of RAC1.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- Proliferation-associated miRNAs-494, -205, -21 and -126 detected by in situ hybridization: expression and prognostic potential in breast carcinoma patients.Journal of cancer research and clinical oncology · 2018Article
- Messenger RNA Life-Cycle in Cancer Cells: Emerging Role of Conventional and Non-Conventional RNA-Binding Proteins?International journal of molecular sciences · 2018Review
- RegenDbase: a comparative database of noncoding RNA regulation of tissue regeneration circuits across multiple taxa.NPJ Regenerative medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purpose of reviewThe goals of this review are to examine the usefulness of miRNAs as diagnostic and prognostic biomarkers for cancer and to evaluate the applicability of miRNAs as cancer therapeutics. RECENT
findingsExamination of miRNA milieu from body fluids offers a new alternative for quick, affordable and easy analysis of disease status in patients. Blood-based exosomal miRNAs have increased stability and are an excellent choice for clinical cancer diagnostics and prognostics. Currently, there are many miRNA signatures associated with cancer and progression but there is no consensus among multiple sera and tumor sample studies. Off-target and immunological effects remains an obstacle for use of miRNAs as novel chemotherapeutics in the clinic. Recent developments in nanotechnology and drug delivery systems which target the tumor microenvironment may provide an alternative therapeutic approach with decreased toxicity. SUMMARY: This review critically evaluates the literature investigating the use of miRNAs as biomarkers and their future as potential therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.